{
    "clinical_study": {
        "@rank": "139675", 
        "arm_group": [
            {
                "arm_group_label": "edoxaban group", 
                "arm_group_type": "Experimental", 
                "description": "edoxaban"
            }, 
            {
                "arm_group_label": "dalteparin group", 
                "arm_group_type": "Active Comparator", 
                "description": "dalteparin"
            }
        ], 
        "brief_summary": {
            "textblock": "Edoxaban will be similar to dalteparin in preventing recurrence of acute VTE following an\n      initial index event in cancer subjects."
        }, 
        "brief_title": "Cancer Venous Thromboembolism (VTE)", 
        "condition": [
            "Venous Thromboembolism (VTE)", 
            "Deep Vein Thrombosis (DVT)", 
            "Pulmonary Embolism (PE)", 
            "Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Embolism", 
                "Pulmonary Embolism", 
                "Thromboembolism", 
                "Thrombosis", 
                "Venous Thrombosis", 
                "Venous Thromboembolism"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female subjects with age \u2265 18 years or the otherwise legal lower age\n             according to the country of residence;\n\n          -  Confirmed acute lower extremity proximal DVT or PE for which long term treatment with\n             low molecular weight heparin (LMWH) is indicated;\n\n          -  Cancer, other than basal-cell or squamous-cell carcinoma of the skin;\n\n          -  Able to provide written informed consent.\n\n        Exclusion Criteria:\n\n          -  Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat\n             the current (index) episode of DVT and/or PE;\n\n          -  Treatment with therapeutic doses of an anticoagulant other than that used for\n             pretreatment of the current (index) VTE episode prior to randomization;\n\n          -  Active bleeding or high risk for bleeding contraindicating treatment with LMWH or\n             edoxaban;\n\n          -  Any other contraindication listed in the local labeling of dalteparin, enoxaparin, or\n             edoxaban;"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "February 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02073682", 
            "org_study_id": "DU176b-D-U311"
        }, 
        "intervention": [
            {
                "arm_group_label": "edoxaban group", 
                "intervention_name": "edoxaban", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "dalteparin group", 
                "intervention_name": "Dalteparin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dalteparin", 
                "Heparin, Low-Molecular-Weight"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 25, 2014", 
        "number_of_arms": "2", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "primary efficacy outcome is incidence of recurrent VTE at end of study", 
                "measure": "incidence of recurrent VTE at end of study", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "primary safety outcome is incidence of clinically relevant bleeding while on treatment", 
                "measure": "incidence of of clinically relevant bleeding while on treatment", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02073682"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Daiichi Sankyo Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Daiichi Sankyo Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "N/A", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}